NewcelX (NCEL) announced a collaborative research agreement with Eledon Pharmaceuticals (ELDN). The collaboration is designed to advance combination strategies integrating NewcelX’s lead program, NCEL-101, with Eledon’s investigational anti-CD40L monoclonal antibody, tegoprubart, with the goal of supporting durable, immune-protected islet replacement and advancing a potential functional cure for Type 1 Diabetes.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NCEL: